Nathalie Dhédin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Nathalie Dhédin has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
- Ibrahim Yakoub-Agha
CHRU Lille, Lille, France
4 shared publications R. Duléry
4 shared publicationsC.-E. Bulabois
3 shared publicationsD. Blaise
Unité de transplantation médullaire, institut Paoli Calmettes, 232, boulevard Sainte-Marguerite, BP 156, 13273 Marseille, France
3 shared publicationsJ.-O. Bay
3 shared publicationsK. Bilger
3 shared publications
Latest Publications
- 1 August 2014
- Published by Elsevier in Pathologie Biologie
- Vol. 62 (4) , 180-184
Greffes de cellules souches hématopoïétiques à partir d’un donneur haplo-identique : recommandations de la SFGM-TC (première partie)
- 1 August 2014
- Published by Elsevier in Pathologie Biologie
- Vol. 62 (4) , 180-184
Greffes de cellules souches hématopoïétiques à partir d’un donneur haplo-identique : recommandations de la SFGM-TC (première partie)
- 1 August 2014
- Published by Elsevier in Pathologie Biologie
- Vol. 62 (4) , 185-189
Greffes de cellules souches hématopoïétiques à partir d’un donneur haploidentique : recommandations de la SFGM-TC (deuxième partie)
- 1 August 2014
- Published by Elsevier in Pathologie Biologie
- Vol. 62 (4) , 185-189
Greffes de cellules souches hématopoïétiques à partir d’un donneur haploidentique : recommandations de la SFGM-TC (deuxième partie)
- 1 August 2013
- Published by Elsevier in Pathologie Biologie
- Vol. 61 (4) , 155-157
Conduite à tenir devant une anomalie biologique découverte lors du bilan pré-don cellules souches hématopoïétiques : sérologie IgM positive pour le cytomégalovirus, le virus d’Epstein-Barr, la toxoplasmose, ou la syphilis
- 1 August 2013
- Published by Elsevier in Pathologie Biologie
- Vol. 61 (4) , 155-157
Conduite à tenir devant une anomalie biologique découverte lors du bilan pré-don cellules souches hématopoïétiques : sérologie IgM positive pour le cytomégalovirus, le virus d’Epstein-Barr, la toxoplasmose, ou la syphilis
- 1 August 2013
- Published by Elsevier in Pathologie Biologie
- Vol. 61 (4) , 158-159
Conduite à tenir devant un problème du donneur de cellules souches hématopoïétiques : test de grossesse positif et gammapathie monoclonale
- 1 August 2013
- Published by Elsevier in Pathologie Biologie
- Vol. 61 (4) , 158-159
Conduite à tenir devant un problème du donneur de cellules souches hématopoïétiques : test de grossesse positif et gammapathie monoclonale
- 25 January 2010
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 45 (9) , 1471-1473
Therapy-related myelodysplastic syndrome after allogeneic BMT: successful treatment by donor lymphocyte infusions
- 25 January 2010
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 45 (9) , 1471-1473
Therapy-related myelodysplastic syndrome after allogeneic BMT: successful treatment by donor lymphocyte infusions
- 15 January 2010
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 95 (6) , 950-955
Allogeneic hematopoietic stem cell transplantation allows long-term complete remission and curability in high-risk Waldenstrom's macroglobulinemia. Results of a retrospective analysis of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire
Background Patients with poor-risk Waldenström’s macroglobulinemia have suboptimal response and early post-treatment relapse with conventional therapies. Hence, new therapeutic approaches such as allogeneic stem cell transplantation should be evaluated in these patients. Design and Methods We examined the long-term outcome of allogeneic stem cell transplantation in Waldenström’s macroglobulinemia by studying the records of 24 patients reported in the SFGM-TC database and one transplanted in the bone marrow unit in Hamburg. Results Median age at the time of transplant was 48 years (range, 24–64). The patients had previously received a median of 3 lines of therapy (range, 1–6) and 44% of them had refractory disease at time of transplant. Allogeneic stem cell transplantation after myeloablative (n=12) or reduced-intensity (n=13) conditioning yielded an overall response rate of 92% and immunofixation-negative complete remission in 50% of evaluable patients. With a median follow-up of 64 months among survivors (range, 11–149 months), 5-year overall survival and progression-free survival rates were respectively, 67% (95% CI: 46–81) and 58% (95% CI: 38–75). The 5-year estimated risk of progression was 25% (95% CI: 10–36%), with only one relapse among the 12 patients who entered complete remission, versus 5 in the 12 patients who did not. Only one of the 6 relapses occurred more than three years post-transplant. Conclusions Allogeneic stem cell transplantation yields a high rate of complete remissions and is potentially curative in poor-risk Waldenström’s macroglobulinemia.
- 15 January 2010
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 95 (6) , 950-955
Allogeneic hematopoietic stem cell transplantation allows long-term complete remission and curability in high-risk Waldenstrom's macroglobulinemia. Results of a retrospective analysis of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire
Background Patients with poor-risk Waldenström’s macroglobulinemia have suboptimal response and early post-treatment relapse with conventional therapies. Hence, new therapeutic approaches such as allogeneic stem cell transplantation should be evaluated in these patients. Design and Methods We examined the long-term outcome of allogeneic stem cell transplantation in Waldenström’s macroglobulinemia by studying the records of 24 patients reported in the SFGM-TC database and one transplanted in the bone marrow unit in Hamburg. Results Median age at the time of transplant was 48 years (range, 24–64). The patients had previously received a median of 3 lines of therapy (range, 1–6) and 44% of them had refractory disease at time of transplant. Allogeneic stem cell transplantation after myeloablative (n=12) or reduced-intensity (n=13) conditioning yielded an overall response rate of 92% and immunofixation-negative complete remission in 50% of evaluable patients. With a median follow-up of 64 months among survivors (range, 11–149 months), 5-year overall survival and progression-free survival rates were respectively, 67% (95% CI: 46–81) and 58% (95% CI: 38–75). The 5-year estimated risk of progression was 25% (95% CI: 10–36%), with only one relapse among the 12 patients who entered complete remission, versus 5 in the 12 patients who did not. Only one of the 6 relapses occurred more than three years post-transplant. Conclusions Allogeneic stem cell transplantation yields a high rate of complete remissions and is potentially curative in poor-risk Waldenström’s macroglobulinemia.
- 15 March 2007
- Published by Wolters Kluwer Health in Transplantation
- Vol. 83 (5) , 554-560
Telemetric Monitoring of Pulmonary Function After Allogeneic Hematopoietic Stem Cell Transplantation
Background. Late-onset noninfectious pulmonary complications (LONIPC) are both frequent and severe after allogeneic hematopoietic stem cell transplantation (HSCT). The high mortality rate (40–80%) may be related to delayed diagnosis. We assessed the use of telemetric home surveillance of pulmonary function for early diagnosis of LONIPC in transplant recipients. Methods. This prospective study monitored pulmonary function in 37 allogeneic HSCT recipients. About 3 months after HSCT, they received a portable spirometer that measured forced vital capacity, forced expiratory volume per second, and midexpiratory flow 25–75 (MEF25–75). Data were transmitted twice weekly by telephone. Conventional plethysmography confirmed any significant deterioration (>20%). Results. Thirteen episodes of spirometric deterioration were detected by telemetry in 11 patients during a median 17-month (4–41) follow-up period after transplantation. In these cases, examinations including spirometry, high-resolution thoracic computed tomography and bronchoalveolar lavage diagnosed LONIPC in eight episodes in seven patients (cumulative incidence 23.4%, SE 0.08, at month 24 after transplant): bronchiolitis obliterans (BO, n=3), interstitial pneumonia (IP, n=4), or both BO and IP (n=1). Five episodes improved and three were stabilized with increased immunosuppressive therapy. At the last follow-up, of the seven patients with LONIPC, one successfully stopped immunosuppressive therapy, two were receiving low-dose mycophenolate mofetil, and four were receiving low-dose corticosteroid therapy. There were no cases of respiratory failure and no patient died from LONIPC. Conclusion. Telemetric home monitoring of pulmonary function is a useful procedure for early diagnosis of LONIPC before clinical pulmonary symptoms and may improve outcome after allogeneic HSCT.
- 15 March 2007
- Published by Wolters Kluwer Health in Transplantation
- Vol. 83 (5) , 554-560
Telemetric Monitoring of Pulmonary Function After Allogeneic Hematopoietic Stem Cell Transplantation
Background. Late-onset noninfectious pulmonary complications (LONIPC) are both frequent and severe after allogeneic hematopoietic stem cell transplantation (HSCT). The high mortality rate (40–80%) may be related to delayed diagnosis. We assessed the use of telemetric home surveillance of pulmonary function for early diagnosis of LONIPC in transplant recipients. Methods. This prospective study monitored pulmonary function in 37 allogeneic HSCT recipients. About 3 months after HSCT, they received a portable spirometer that measured forced vital capacity, forced expiratory volume per second, and midexpiratory flow 25–75 (MEF25–75). Data were transmitted twice weekly by telephone. Conventional plethysmography confirmed any significant deterioration (>20%). Results. Thirteen episodes of spirometric deterioration were detected by telemetry in 11 patients during a median 17-month (4–41) follow-up period after transplantation. In these cases, examinations including spirometry, high-resolution thoracic computed tomography and bronchoalveolar lavage diagnosed LONIPC in eight episodes in seven patients (cumulative incidence 23.4%, SE 0.08, at month 24 after transplant): bronchiolitis obliterans (BO, n=3), interstitial pneumonia (IP, n=4), or both BO and IP (n=1). Five episodes improved and three were stabilized with increased immunosuppressive therapy. At the last follow-up, of the seven patients with LONIPC, one successfully stopped immunosuppressive therapy, two were receiving low-dose mycophenolate mofetil, and four were receiving low-dose corticosteroid therapy. There were no cases of respiratory failure and no patient died from LONIPC. Conclusion. Telemetric home monitoring of pulmonary function is a useful procedure for early diagnosis of LONIPC before clinical pulmonary symptoms and may improve outcome after allogeneic HSCT.
- 1 February 2007
- Vol. 24 (2) , 145-54
[Management of the pulmonary complications of haematological malignancy].
The high frequency of pulmonary complications of haematological malignancy and the increasing number of patients treated for these disorders make it important that the respiratory physician has a structured diagnostic approach according to: 1 the immune deficiency due to the malignancy and/or the treatment administered; 2 the factors that can modify the risk of infection (anti infection prophylaxis and/or pre-emptive treatment); 3 co-morbidities; 4 extra-pulmonary manifestations. Two main situations can be identified: The patient is aplasic: Initially the pneumonias are predominantly of bacterial origin but may be fungal if the neutropenia is prolonged. The respiratory physician is faced with two problems: 1 the diagnosis of pneumonia; this may be helped by CT scanning; 2 The choice of antibiotics; this will depend on previous investigations. The patient is not aplasic: The lung disease may have many causes, mainly infectious but also drug related, tumoral, haemorrhagic or embolic. The main problem is the correct choice of investigations to establish an aetiological diagnosis. The collection of data according to a pre-established protocol based on simple factors (study of the notes and clinical examination) is one of the key elements for improving the prognosis of these patients whose management should be multidisciplinary following a pre-defined plan.
- 1 February 2007
- Vol. 24 (2) , 145-54
[Management of the pulmonary complications of haematological malignancy].
The high frequency of pulmonary complications of haematological malignancy and the increasing number of patients treated for these disorders make it important that the respiratory physician has a structured diagnostic approach according to: 1 the immune deficiency due to the malignancy and/or the treatment administered; 2 the factors that can modify the risk of infection (anti infection prophylaxis and/or pre-emptive treatment); 3 co-morbidities; 4 extra-pulmonary manifestations. Two main situations can be identified: The patient is aplasic: Initially the pneumonias are predominantly of bacterial origin but may be fungal if the neutropenia is prolonged. The respiratory physician is faced with two problems: 1 the diagnosis of pneumonia; this may be helped by CT scanning; 2 The choice of antibiotics; this will depend on previous investigations. The patient is not aplasic: The lung disease may have many causes, mainly infectious but also drug related, tumoral, haemorrhagic or embolic. The main problem is the correct choice of investigations to establish an aetiological diagnosis. The collection of data according to a pre-established protocol based on simple factors (study of the notes and clinical examination) is one of the key elements for improving the prognosis of these patients whose management should be multidisciplinary following a pre-defined plan.